ストックスクリーナーアプリを入手
0.78
2.80%
-0.0225
アフターアワーズ：
.78
前日終値:
$0.8025
開ける：
$0.82
24時間の取引高:
719.00K
Relative Volume:
1.15
時価総額：
$31.20M
収益：
-
当期純損益:
$-35.58M
株価収益率:
-0.2943
EPS:
-2.65
ネットキャッシュフロー:
$-42.82M
1週間 パフォーマンス:
-10.45%
1か月 パフォーマンス:
-22.77%
6か月 パフォーマンス:
-47.65%
1年 パフォーマンス:
-37.60%
1日の値動き範囲:
$0.77
$0.838
1週間の範囲:
$0.77
$0.894
52週間の値動き範囲:
$0.77
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
ITRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.78 | 32.10M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-28 | アップグレード | Gabelli & Co | Sell → Hold |
| 2021-03-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | ダウングレード | Gabelli & Co | Buy → Sell |
| 2019-12-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Iterum Therapeutics Plc (ITRM) 最新ニュース
How strong is Iterum Therapeutics plc company’s balance sheetMarket Forecast Target Finder For 2025 - jammulinksnews.com
What is the dividend policy of Iterum Therapeutics plc stockMaximize gains with data-driven stock picks - jammulinksnews.com
What are analysts’ price targets for Iterum Therapeutics plc in the next 12 monthsUnmatched market performance - jammulinksnews.com
How to use a screener to detect Iterum Therapeutics plc breakoutsDaily Market Momentum and Pressure Analysis - Newser
What moving averages say about Iterum Therapeutics plcStock Entry Point Planner with Volume Spike - Newser
What institutional investors are buying Iterum Therapeutics plc stockUnlock daily stock market insights for success - jammulinksnews.com
Iterum Therapeutics plc Company Revenue and Profit Trends: A Deep DiveTrend Following Trades - metal.it
Iterum Therapeutics plc Stock Analysis and ForecastFree Stock Market Trend Analysis - PrintWeekIndia
Is Iterum Therapeutics plc a good long term investmentSuperior risk-adjusted returns - Autocar Professional
What drives Iterum Therapeutics plc stock priceConsistently exceptional gains - Autocar Professional
Iterum Therapeutics Plc (ITRM) Stock: A Year of Market Movement, Down and Up - investchronicle.com
What analysts say about Iterum Therapeutics plc stockHigh-profit capital plays - jammulinksnews.com
Why Iterum Therapeutics plc stock attracts strong analyst attentionMassive Profit Potential - Newser
What makes Iterum Therapeutics plc stock price move sharplyWatchlist Winner Update - Newser
How Iterum Therapeutics plc stock performs during market volatilityFree Access to Investment Community - Newser
OneDigital Investment Advisors LLC Invests $124,000 in Iterum Therapeutics PLC (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (NASDAQ:ITRM) Trading Down 4.2% – Here’s What Happened - Defense World
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Iterum Strengthens Launch Strategy: 30-Year Pharma Veteran Christine Coyne to Lead ORLYNVAH Commercialization - Stock Titan
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Yahoo Finance
Certain Options of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Certain Ordinary Shares of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Resul - GuruFocus
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Results | ITRM Stock News - GuruFocus
New Antibiotic Shows Promise Against Drug-Resistant UTIs: NEJM Evidence Reveals 9.2% Multi-Resistance Rate - Stock Titan
Transcript : Iterum Therapeutics plcSpecial Call - MarketScreener
Research Analysts Set Expectations for ITRM FY2026 Earnings - Defense World
Two Sigma Investments LP Invests $45,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships - pharmaphorum
Citadel Advisors LLC Acquires Shares of 21,207 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics Plc (ITRM) 財務データ
収益
当期純利益
現金流量
EPS
1.32%
1.06%
大文字化:
|
ボリューム (24 時間):